Today: 9 June 2026
Grab Stock Barely Moves As Taiwan Push And Singapore Merchant Plan Put Growth Back In Focus
9 June 2026
2 mins read

Grab Stock Barely Moves As Taiwan Push And Singapore Merchant Plan Put Growth Back In Focus

Singapore, June 9, 2026, 20:06 (SGT)

  • Grab’s Nasdaq-listed shares were near flat in pre-market trading, last at about $3.33.
  • The company announced a Singapore food-and-beverage merchant programme and Taiwan partner commitments on Tuesday.
  • Investors are weighing new market expansion and financial-services growth against regulation, incentives and consumer spending pressure.

Grab Holdings’ U.S.-listed shares were little changed before the Nasdaq open on Tuesday after the Southeast Asian ride-hailing and delivery group announced fresh merchant-support moves in Singapore and partner commitments in Taiwan, where its proposed foodpanda deal still needs approval.

The stock last traded around $3.33, giving Grab a market value of about $13.2 billion, according to current market data. Nasdaq’s regular session had not yet opened; the exchange lists normal trading hours at 9:30 a.m. to 4:00 p.m. Eastern Time, with pre-market trading from 4:00 a.m. to 9:30 a.m.

The news matters because Grab is trying to show that growth can still come from its core app, not just from cost cuts. Its latest Singapore programme is aimed at smaller food-and-beverage merchants facing higher costs and tougher consumer spending, while the Taiwan statement is tied to its planned entry through foodpanda Taiwan, a Delivery Hero business.

Grab Singapore launched “Grab Full House Mission” on Tuesday, saying the programme would combine nationwide delivery deals, Dine Out precinct campaigns, merchant workshops, neighbourhood outreach and onboarding support. The company said Grab-funded promotions would offer consumers up to 15% off menu-wide on GrabFood, and it would sponsor a S$388 onboarding package for as many as 70 merchants through December 2026. Grab

“A full house means more than just filled tables,” said Alejandro Osorio, managing director of Grab Singapore. Enterprise Singapore’s Jeannie Lim said local food businesses needed “digital tools” and “increased reach” as consumer demand changes. Grab

In Taiwan, Grab said it would offer delivery partners a zero-cost transition, next-day onboarding and dedicated voice support if its proposed acquisition of foodpanda Taiwan is approved. It also pointed to its Just-In-Time Allocation technology, which is meant to cut courier waiting time by matching dispatches more closely with food preparation.

Yee Wee Tang, Grab’s group managing director for operations, said the company approached Taiwan with “deep respect and humility.” He added that, if approved, Grab would comply with local law and “compete fairly,” while engaging regulators and unions. Grab

The Taiwan push gives Grab a competitive link to Delivery Hero, whose foodpanda Taiwan delivery business Grab agreed to buy. Grab said in May the planned acquisition would mark its first market expansion outside Southeast Asia and was expected to close in the second half of 2026, subject to regulatory approval and other conditions.

The broader equity backdrop was steadier after the Nasdaq Composite rebounded on Monday from a three-day losing streak, helped by a bounce in technology stocks. That offered some support for growth shares, though Grab’s own move remained muted before the open.

Grab’s most recent results are the main financial anchor for the shares. The company reported first-quarter revenue of $955 million, up 24% from a year earlier, and adjusted EBITDA of $154 million. Adjusted EBITDA means earnings before interest, tax, depreciation and amortisation, with some items removed; investors use it as a rough gauge of operating profitability.

Chief Financial Officer Peter Oey called the quarter a sign of “consistent execution” and “growing operating leverage.” Grab kept its 2026 revenue guidance at $4.04 billion to $4.10 billion and adjusted EBITDA guidance at $700 million to $720 million. Grab

There is another moving part. Grab said on May 20 it would consolidate PT Super Bank Indonesia after Singtel transfers its stake in the Indonesian digital bank to GXS Bank, Grab’s digital banking joint venture with Singtel. Superbank serves more than 6 million customers and will be folded into Grab’s Financial Services segment, the filing showed.

Analysts have stayed broadly constructive. Phillip Securities Research analyst Helena Wang wrote on May 11 that she maintained a buy call and a US$7 target price, calling Grab a “long-term structural winner” in Southeast Asia, helped by demand momentum, improving profitability and data advantages. POEMS

But the downside case is still clear. Taiwan approval is not assured, and any conditions imposed by regulators or labour groups could slow the foodpanda integration or raise costs. In Singapore and other markets, promotions and partner support can defend market share, but they may also pressure margins if consumer demand weakens or rivals respond with heavier discounts.

Stock Market Today

  • Wheat Prices Mixed as Winter Wheat Gains on U.S. Crop Progress
    June 9, 2026, 9:22 AM EDT. Wheat markets closed mixed on Monday, with winter wheat futures rising across Chicago and Kansas City exchanges, while Minneapolis spring wheat fell slightly. The U.S. Department of Agriculture's Crop Progress report showed 92% of winter wheat heading, 7% ahead of average, and spring wheat planting at 98%, with improving crop conditions. Export inspections dropped 20.65% from last week but marketing year shipments rose 9.13% compared to last year. Ukraine's wheat crop estimate increased by 1.8 million tonnes to 21.7 million tonnes. Futures finished with Chicago SRW wheat up 1 to 3 ¼ cents and Kansas City HRW wheat up 2 ¼ to 9 cents, contrasting the modest decline in Minneapolis spring wheat.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
CCSC stock pops ahead of the bell as Nasdaq deadline looms
Previous Story

CCSC stock pops ahead of the bell as Nasdaq deadline looms

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus
Next Story

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Go toTop